SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced on October 5, 2026, that it has submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market.
This development matters because it signals a potential shift in the U.S. surgical robotics landscape, where high costs have historically limited access to robotic-assisted surgery. SS Innovations aims to make robotic surgery affordable and accessible to a larger segment of the global population. The SSi Mantra system is a modular, multi-arm robotic platform with advanced features such as 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information. It also includes the optional SSi MantrAsana tele-surgeon console, which offers portability and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries, and has been clinically validated in India in more than 190 different types of surgical procedures.
If cleared by the FDA, the SSi Mantra could increase competition in the U.S. robotic surgery market, potentially lowering costs and expanding access for patients and hospitals. The company’s focus on affordability and accessibility could disrupt a market currently dominated by a few major players. For investors, the FDA submission and anticipated review timeline represent a critical milestone. SS Innovations International (NASDAQ: SSII) is traded on the Nasdaq, and the outcome of the FDA review could significantly impact its stock performance. The company’s efforts to enter the U.S. market are part of its broader strategy to expand the global presence of its surgical robotic solutions. For more details, visit the full press release at https://ibn.fm/A6dJ8. The company’s website, ssinnovations.com, provides additional information, and updates are also available via LinkedIn. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. Forward-looking statements involve risks and uncertainties, and actual results may differ materially. For full terms of use and disclaimers, see https://IBN.ai/Disclaimer.
